UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

	(Amendment No. 2)*				
	Astria Therapeutics, Inc.				
	(Name of Issuer)				
	Common Stock, \$0.001 par value				
	(Title of Class of Securities)				
	04635X102				
	(CUSIP Number)				
	December 31, 2023				
	(Date of Event which Requires Filing of this Statement)				
Ch	eck the appropriate box to designate the rule pursuant to which this Schedule is filed:				
	Rule 13d-1(b)				
X	Rule 13d-1(c)				
	Rule 13d-1(d)				
*	The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.				
	The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the				
_					

CUSIF	No.	0463	5X1	02

1	NAMES OF REPORTING PERSONS				
	Vivo Opportunity Fund Holdings, L.P.				
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)			PRIATE BOX IF A MEMBER OF A GROUP (See Instructions)		
	(a) 🗆	(a)			
	` '	(b) ⊠			
3	SEC USE C	SEC USE ONLY			
4 CITIZENSHIP OR PLACE OF ORGANIZATION		LACE OF ORGANIZATION			
	Delaware				
		5	SOLE VOTING POWER		
			2,482,727 (1)		
	BER OF ARES	6	SHARED VOTING POWER		
BENEF	ICIALLY		0		
REPO	BY EACH RTING	7	SOLE DISPOSITIVE POWER		
	RSON ITH		2,482,727 (1)		
		8	SHARED DISPOSITIVE POWER		
			0		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	2,482,727 (1)				
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)				
11	PERCENT	OF CLAS	S REPRESENTED BY AMOUNT IN ROW (9)		
	4.5% (2)				
12 TYPE OF REPORTING PERSON (See Instructions)			NG PERSON (See Instructions)		
PN					

- (1) The shares of common stock, \$0.001 par value (the "Common Stock") of Astria Therapeutics, Inc. (the "Issuer") are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
- (2) Based on 54,666,012 shares of Common Stock outstanding, as reported in the Prospectus Supplement to the Registration Statement on Form S-3 dated December 15, 2023 (File No. 333-276057), filed by the Issuer with the Securities and Exchange Commission (the "SEC") on January 31, 2024.

CHISID	Nο	04635X102
CUSII	INU.	0 1 033A104

1	NAMES OF REPORTING PERSONS				
Vivo Opportunity, LLC					
2	CHECK TH	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)			
	(a) 🗆				
	(b) ⊠				
3	SEC USE ONLY				
4	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware				
		5	SOLE VOTING POWER		
			2,482,727 (1)		
	BER OF ARES	6	SHARED VOTING POWER		
BENEF	TCIALLY		0		
REPC	BY EACH ORTING	7	SOLE DISPOSITIVE POWER		
	RSON TTH		2,482,727 (1)		
		8	SHARED DISPOSITIVE POWER		
			0		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	2,482,727 ⁽¹⁾				
10	CHECK BO	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)			
11	PERCENT	OF CLASS	S REPRESENTED BY AMOUNT IN ROW (9)		
	4.5% (2)	4.5% ⁽²⁾			
12	TYPE OF REPORTING PERSON (See Instructions)				
	00				

- (1) The shares of Common Stock of the Issuer are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
- (2) Based on 54,666,012 shares of Common Stock outstanding, as reported in the Prospectus Supplement to the Registration Statement on Form S-3 dated December 15, 2023 (File No. 333-276057), filed by the Issuer with the SEC on January 31, 2024.

Ітем 1.	(a)	Name (of Issuer:			
		Astria	Therapeutics, Inc.			
	(b)	Addres	Address of Issuer's Principal Executive Offices:			
		75 Stat	te Street, Suite 1400			
		Boston	n, Massachusetts, 02109			
Ітем 2.	(a)	Name (of Person Filing:			
		This So	chedule 13G/A is filed jointly by Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC			
	(b)	Addres	SS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:			
		192 Ly	rtton Avenue, Palo Alto, CA 94301			
	(c)	CITIZE	NSHIP:			
		Vivo C	Opportunity Holdings, L.P. is a Delaware limited partnership.			
		Vivo C	Opportunity, LLC is a Delaware limited liability company.			
(d) Title of Class of Securities: Common Stock, par value \$0.001 per share			of Class of Securities:			
			on Stock, par value \$0.001 per share			
	(e) CUSIP Number:					
04635X102			X102			
I тем 3.		IF THIS	IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b), OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:			
	(a)	□ В	Broker or dealer registered under Section 15 of the Act.			
	(b)	□ В	Bank as defined in Section 3(a)(6) of the Act.			
	(c)	□ Ir	nsurance company as defined in Section 3(a)(19) of the Act.			
	(d)	□ Ir	nvestment company registered under Section 8 of the Investment Company Act of 1940.			
	(e)	□ A	an investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);			
	(f)	□ A	an employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);			
	(g)	□ A	a parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);			
	(h)	□ A	a savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;			
	(i)	□ A	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;			
	(j)	□ A	a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);			
	(k)		Group, in accordance with § 240.13d-1(b)(l)(ii)(K).			
	If fi	iling as	a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution:			
	Not	t Applic	able.			

Item 4. Ownership.

(a) Amount beneficially owned:

The 2,482,727 shares of Common Stock of the Issuer are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

(b) Percent of class:

4.5%

(c) Number of shares as to which such person has:

- (i) Sole power to vote or to direct the vote: 2,482,727 shares
- (ii) Shared power to vote or to direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of: 2,482,727 shares
- (iv) Shared power to dispose of or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Vivo Opportunity Fund Holdings, L.P. February 13, 2024 (Date) /s/ Kevin Dai (Signature) Managing Member (Title) Vivo Opportunity, LLC February 13, 2024 (Date) /s/ Kevin Dai (Signature) Managing Member (Title)